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Abstract
Background: Dietary intervention trials rely on self-reported measures of intake for assessment
of energy and macronutrient composition. Dietary fat intake is of particular interest due to strong
associations with pathophysiology. In epidemiological trials phospholipid fatty acid composition may
reflect composition of habitual diet, although strong correlations have been identified only for
essential polyunsaturated fatty acids (PUFAs). Preliminary evidence shows that saturated fatty acids
(SFA) C15:0 and C17:0 may be acceptable biomarkers. This study measured changes in erythrocyte
membrane fatty acids during a period of strictly controlled fat feeding to investigate their use as a
short-term marker of compliance, particularly for intake of SFAs.
Results: This was a randomised cross-over trial in which diet was provided and strictly controlled.
20 healthy, male subjects were given a 40 energy % (en%) fat diet, high in saturated (high-SFA, 20
en%) or unsaturated (high-USFA, 24 en%) fatty acids for 2 periods of 3 weeks. Subjects were
residential during intervention with all food and beverages provided. Dietary composition was
verified by direct chemical analysis. Blood samples were collected on days 1,7,14, 21 and analysed
for red blood cell (RBC) membrane fatty acid composition. Pearson correlation showed RBC fatty
acid composition to mimic dietary composition by 3 weeks, but the relationships were weak. Of
the SFAs only RBC C16:0 decreased in response to decreased dietary content on high-USFA
treatment (ANOVA, diet, P < 0.05). Of the USFAs, higher levels of C18:1 MUFA, C20:4 and C22:6
long chain PUFA on high-USFA diet lead to higher C18:1, C20:4 and C22:6 within RBCs (ANOVA,
time*diet, P < 0.05). Pearson's correlation was significant between dietary and RBC fatty acids
during the 21d dietary manipulation for C18:1, and C20:5, C22:6 only (P < 0.05).
Conclusion: RBC membrane fatty acids cannot reliably be used as an independent measure of
compliance for dietary SFA intake in short-term studies. The MUFA oleic acid and PUFAs EPA and
DHA may be more useful as markers of compliance during short term intervention trials.
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Background
Assessment of dietary intake through food records or even
weighed food intake is commonly subject to bias, pro-
vides only a poor estimate of current and/or habitual diet,
and leads to widespread misreporting of energy and nutri-
ent intake [1-7]. Biochemical biomarkers provide reason-
able independent assessment tools for some
micronutrients [8] but are less widely used for macronu-
trients such as fatty acids where even qualitative relation-
ships between many important dietary and biological
lipids remain to be well demonstrated. One of the major
stumbling blocks in assessing the usefulness of fatty acid
biomarkers is the use of reported intakes as the compara-
tor in many [9-13] although not all [14-17] validation
studies. We were interested in evaluating the use of
biomarkers to assess the 3 major classes of fatty acids in
subjects whose dietary intake was both fixed and known
through provision of all dietary fats during a residential
nutrition trial, with a particular interest in determining
possible biomarkers of dietary SFA.
The strength of correlation between dietary intake and
biomarker appears to vary considerably between individ-
ual fatty acids [14]. It would be expected that biomarkers
of the ω-3 and ω-6 polyunsaturates (PUFA), such as α-
linolenic (ALA, C18:3ω-3) or linoleic acid (LA, C18.2ω-
6), would have the strongest association with intake
[12,18,19] since the inability to generate double-bonds
more than 9 carbons from the carboxyl or delta end of the
fatty acid ensure these PUFA may be derived from diet
alone. There is some suggestion that SFA with an odd
number of carbon atoms, such as pentadecanoic (C15:0)
and heptadecanoic acid (C17:0) predominantly from
dairy fats, may also provide a good marker of their respec-
tive intakes since they can be synthesised only by bacterial
flora of ruminants [9,10]. The monounsaturated fats
(MUFA) and the SFA with an even number of carbon
atoms may be less well correlated with intake [20-26]
since their derivation is not dependent on intake from
diet alone. Interestingly however a MUFA-enriched diet
has been shown to increase circulating MUFA content in
several trials [12,15,27], but this finding is not universal
Table 1: Composition of the two intervention diets as measured by direct chemical analysis
High SFA High USFA
Energy intake, EI (range, MJ/d) 10.5–15.5 10.5–16.0
EI (mean, MJ/d) 13.1 ± 0 13.2 ± 0.2
CHO, % of energy 47 ± 0.6 48 ± 0.6
Protein, % of energy 13 ± 0.7 13 ± 0.7
Fat, % of energy 40 ± 0.8 39 ± 0.8
Cholesterol (mg/d) 298 ± 2 280 ± 2
Total SFA (calculated, en%) 20 ± 0.3 15 ± 0.3
SFA profile (g/d)
C10:0 Capric acid 2.2 ± 0.2 1.7 ± 0.3*
C12:0 Lauric acid 8.7 ± 0.9 9.7 ± 1.4*
C14:0 Myristic acid 7.8 ± 0.7 5.9 ± 0.6**
C15:0 Pentadecanoic acid 0.8 ± 0.1 0.6 ± 0.1***
C16:0 Palmitic acid 24.6 ± 1.3 17.8 ± 0.8***
C17:0 Heptadecanoic acid 0.35 ± 0.04 0.42 ± 0.03***
C18:0 Stearic acid 8.3 ± 0.4 11.3 ± 0.4***
Total MUFA (calculated, en%) 6 ± 0.2 8 ± 0.1
MUFA profile (g/d)
C16:1n-7 Palmitoleic acid 1.8 ± 1.1 0.9 ± 0.8
C18:1n-9 Oleic acid 21.3 ± 1.7 29.5 ± 1.5***
Total PUFA (calculated, en%) 14 ± 0.1 16 ± 0.2
PUFA profile (g/d)
C18:2n-6 Linoleic acid [LA] 23.1 ± 1.0 30.0 ± 0.9***
C18:3n-3 α-Linolenic acid [ALA] 1.8 ± 0.3 2.4 ± 0.3**
C20:4n-6 Arachidonic acid [AA] 3.6 ± 0.4 4.1 ± 0.4***
C20:5n-3 Eicosapentaenoic acid [EPA] 0.6 ± 0.1 0.6 ± 0.1
C22:4n-6 Docosatetraenoic acid nd nd
C22:6n-3 Docosahexaenoic acid [DHA] 0.5 ± 0.1 0.6 ± 0.1
Results are the mean values for 6 duplicate portions. Mean ± sd. SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, 
polyunsaturated fatty acid. Minor fractions of fatty acid profiles not shown. Significantly different from high SFA diet: *P < 0.05, ** P < 0.01, ***P < 
0.001, nd, not detectableLipids in Health and Disease 2005, 4:30 http://www.lipidworld.com/content/4/1/30
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[13,22,23,28]. There is less evidence of potentially useful
SFA biomarkers [12], although a positive relationship has
been observed in some studies [29,30].
The purpose of this trial therefore was to measure changes
in erythrocyte membrane fatty acids during a period of
controlled fat feeding in order to investigate both the rate
at which dietary change alters membrane composition to
assess potential use as a short-term marker of compliance,
and also whether a qualitative biomarker for intake of SFA
can be identified when dietary intake is known and rigor-
ously controlled.
Results
Twenty men completed both arms of the intervention.
Mean age was 23 (4.1, sd) years, body mass index (BMI)
was 21.6 (2.6, sd) kg/m2 and all were healthy as assessed
by self-report and a biochemical screening panel. The diet
was designed to be of typical of western composition,
with 40 % of total energy derived from fat, 47 en% carbo-
hydrate and 13 en% protein. There was no significant dif-
ference between total energy intake or macronutrient
composition between treatments (P > 0.05, Table 1) in
this cross-over trial. The high-SFA and high-USFA dairy
lipids used in the two diets resulted in a significant differ-
ence between dietary treatments for all fatty acids meas-
ured (paired t-test, P < 0.05; C10:0, C12:0, C14:0, C15:0,
C16:0, C17:0, C18:0, C18:1, C18:2, C18:3, C20:4, C22:6,
see Table 1) other than C16:1 trans and the n-3 PUFA
marine oil ecosapentaenoic acid (EPA, C20:5). The major
changes in SFA were in myristic (C14:0, -1.9 g/d, -24%),
palmitic (C16:0, -6.8 g/d, -28%) and stearic (C18:0, +3.0
g/d, +36%) acids. The major changes in USFA were in
oleic (C18:1, +8.2 g/d, +39%), linoleic (LA, C18:2n-6,
+6.9 g/d, +30%), α-linolenic (ALA, C18:3n-3, +0.6 g/d,
+33%) and arachidonic (AA, C20:4n-6, +0.5 g/d, +14%)
acids.
The erythrocyte fatty acid profile measured on day 21, fol-
lowing 3 weeks of high-SFA and high-USFA treatment are
shown in Table 2. There was a significant difference in red
blood cell (RBC) fatty acid profile between dietary treat-
ments for C14:0, C16:0, C18:0, C18:1 and C20:4 (paired
t-test, P < 0.05). C10:0 and C16:1 could not be detected as
individual peaks on the FAME plots on either diet.
Throughout the 21 day intervention period, RBC fatty acid
profile (Figures 1 &2, middle and right panels) tended to
mimic dietary profile (Figures 1 &2, left panel) for the
majority of fatty acids measured but the relationships
were weak.
SFA
Not all individual SFAs were higher on the high-SFA diet,
although the design of the trial ensured that total SFA con-
tent was higher on this treatment. Dietary C14:0, C15:0
and C16:0 were higher on the high-SFA treatment (P <
0.01), yet RBC analyses showed palmitic acid (C16:0) to
be the single SFA which was greater following 21 days of
Table 2: Erythrocyte fatty acid profile in 20 healthy men following 21 days on a high saturated or a high unsaturated fat diet
High SFA (% peak area) High USFA (% peak area)
SFA profile
C10:0 Capric acid nd nd
C12:0 Lauric acid 0.36 ± 0.22 0.39 ± 0.23
C14:0 Myristic acid 0.54 ± 0.07 0.49 ± 0.05***
C15:0 Pentadecanoic acid 0.20 ± 0.15 0.17 ± 0.14
C16:0 Palmitic acid 26.27 ± 0.97 25.26 ± 0.89***
C17:0 Heptadecanoic acid 0.48 ± 0.12 0.50 ± 0.12
C18:0 Stearic acid 9.67 ± 0.91 10.31 ± 0.95**
Total SFA 37.5 37.1
MUFA profile
C16:1n-7 Palmitoleic acid nd nd
C18:1n-9 Oleic acid 10.25 ± 0.82 10.70 ± 0.88**
Total MUFA 10.3 10.7
PUFA profile
C18:2n-6 Linoleic acid [LA] 15.25 ± 1.65 14.99 ± 1.77
C18:3n-3 α-Linolenic acid [ALA] 0.4 ± 0.2 0.4 ± 0.2
C20:4n-6 Arachidonic acid [AA] 10.17 ± 1.01 10.6 ± 0.88**
C20:5n-3 Eicosapentaenoic acid [EPA] 0.62 ± 0.13 0.56 ± 0.24
C22:4n-6 Docosatetraenoic acid 1.90 ± 0.42 1.99 ± 0.58
C22:6n-3 Docosahexaenoic acid [DHA] 2.77 ± 0.51 2.82 ± 0.53
Total PUFA 27.7 31.4
SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid. % peak area calculated from fatty acid methyl esters 
(FAMEs). Minor fractions of fatty acid profiles not shown. Significantly different from high SFA diet: *P < 0.05, ** P < 0.01, ***P < 0.001, nd, not 
detectable. Mean ± sdLipids in Health and Disease 2005, 4:30 http://www.lipidworld.com/content/4/1/30
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Dietary (left panel) and red blood cell (RBC, centre and right panels) saturated fatty acid composition during the 3 week high- saturated (high-SFA) and high-unsaturated (high-USFA) dietary treatments Figure 1
Dietary (left panel) and red blood cell (RBC, centre and right panels) saturated fatty acid composition during the 3 week high-
saturated (high-SFA) and high-unsaturated (high-USFA) dietary treatments. Diet was strictly controlled by providing subjects 
with all food and drinks throughout the 6 week residential intervention. Treatments were separated by a minimum 4 week 
wash-out period. Change in RBC membrane fatty acids was measured on day 1, d7, d14 and d21 of each intervention arm (●  
high-SFA, ❍  high-USFA). AUC day 1–21, area under the curve of change in RBC % peak area.Lipids in Health and Disease 2005, 4:30 http://www.lipidworld.com/content/4/1/30
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Dietary (left panel) and red blood cell (RBC, centre and right panels) mono- and polyunsaturated fatty acid composition during  the 3 week high-saturated (high-SFA) and high-unsaturated (high-USFA) dietary treatments Figure 2
Dietary (left panel) and red blood cell (RBC, centre and right panels) mono- and polyunsaturated fatty acid composition during 
the 3 week high-saturated (high-SFA) and high-unsaturated (high-USFA) dietary treatments. Diet was strictly controlled by pro-
viding subjects with all food and drinks throughout the 6 week residential intervention. Treatments were separated by a mini-
mum 4 week wash-out period. Change in RBC membrane fatty acids was measured on day 1, d7, d14 and d21 of each 
intervention arm (●  high-SFA, ❍  high-USFA). AUC day 1–21, area under the curve of change in RBC % peak area.Lipids in Health and Disease 2005, 4:30 http://www.lipidworld.com/content/4/1/30
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the high-SFA diet compared with 21 days of high-USFA
treatment (Figure 1, ANOVA, diet*time, P < 0.05). In con-
trast, dietary C12:0, C17:0 and C18:0 were all lower on
the high-SFA treatment (P < 0.05), but RBC analyses
showed stearic acid (C18:0) to be the single SFA signifi-
cantly lower on the high-SFA relative to high-USFA treat-
ment (ANOVA, diet*time, P < 0.05). With the exception
of C16:0 there were significant increases above baseline
RBC values in response to both treatments in all RBC SFAs
over the 21 day intervention, possibly due to the change
from habitual home diet (ANOVA, time, P < 0.01). RBC
palmitic acid decreased on both treatments over time
(ANOVA, time, P < 0.001).
MUFA
Dietary oleic acid (C18:1) content was significantly higher
on the high-USFA treatment (Figure 2, left panel, P <
0.001), which induced a significantly greater RBC oleic
acid content over 21 days compared to high-SFA diet (Fig-
ure 2, middle and right panels, ANOVA, diet*time, P <
0.05). Both diets caused a decrease in RBC C18:1 content
between baseline and follow-up which was independent
of treatment group (ANOVA, time, P < 0.001).
PUFA
Dietary linoleic (LA, C18:2), α-linolenic (ALA, C18:3),
arachidonic (AA, C20:4) and docosahexaenoic acid
(DHA, C22:6) were all significantly greater on the high-
USFA treatment (Figure 2, left panel, P < 0.05), but only
in the long chain PUFAs AA (C20:4) and DHA (C22:6)
did RBC content differentially increase in response to the
high PUFA diet (Figure 2, middle and right panels,
ANOVA, diet*time, P < 0.01). There was a significant
increase in RBC LA (C18:2) and a decrease in EPA (C20:5)
and DHA (C22:6) content relative to baseline levels over
the 3 weeks of dietary intervention, independent of treat-
ment group (ANOVA, time, P < 0.001), but no significant
change in RBC levels of ALA (C18:3) or AA (C20:4) over
time (ANOVA, time, P > 0.05).
Table 3 shows the Pearson correlations of dietary and RBC
fatty acid composition throughout the 3 week interven-
tion on both dietary treatments. There were significant
correlations between dietary and RBC C14:0 and C18:1
on day 1 of high SFA, and C17:0 and C22:6 on day 1 of
high-USFA diet (P < 0.05) both of which were pre-inter-
vention. During the controlled intervention the analyses
revealed a significant correlation between diet and blood
markers for the MUFA oleic acid on day 14 of the high-
SFA and day 21 of the high-USFA diets respectively (P <
0.05), for EPA throughout the high-SFA treatment (P <
0.05) and DHA throughout both treatments (P < 0.05).
The correlation between diet and RBC fatty acid composi-
tion was by far the strongest and most consistent for the
LCPUFA DHA despite the gradual decrease in RBCs over
time on both high-SFA and high-USFA diets (ANOVA,
time, P < 0.001).
Discussion
This trial was designed to assess whether red blood cell
fatty acids can provide a qualitative short term, independ-
ent measure of dietary lipid intake. We were particularly
interested in the saturated fatty acids since a high intake
has been repeatedly shown to be closely linked to numer-
ous disease states in dietary trials, yet independent mark-
ers of intake are not as yet available. There were a number
of important features of this trial. Firstly that dietary lipid
intake was carefully measured and rigorously controlled
throughout the intervention by provision of foods in a
residential setting. The disadvantage of such a protocol
Table 3: Pearson correlations between diet and RBC fatty acid composition for the 2 dietary treatments (r values)
High SFA High USFA
Fatty acid day 1 day 7 day 14 day 21 day 1 day 7 day 14 day 21
SFA
C12:0 0.251 0.161 0.101 0.141 0.100 0.140 0.040 0.001
C14:0 0.497* 0.231 0.179 0.075 0.248 0.330 0.163 0.145
C15:0 0.180 0.390* 0.121 0.265 0.336 0.106 0.036 0.026
C16:0 0.143 0.169 0.134 0.193 0.356 0.238 0.054 0.251
C17:0 0.229 0.062 0.200 0.226 0.391* 0.101 0.053 0.061
C18:0 0.200 0.101 0.339 0.124 0.213 0.351 0.379* 0.326
MUFA
C18:1 0.386* 0.157 0.412* 0.226 0.008 0.218 0.336 0.421*
PUFA
C18:2 0.315 0.319 0.509* 0.223 0.237 0.278 0.260 0.304
C18:3 0.262 0.143 0.313 0.218 0.028 0.169 0.121 0.155
C20:4 0.078 0.114 0.144 0.038 0.014 0.191 0.202 0.130
C20:5 0.197 0.419* 0.473* 0.487* 0.257 0.223 0.243 0.167
C22:6 0.373* 0.447* 0.433* 0.369* 0.408* 0.480* 0.491* 0.394*
SFA, saturated fatty acid; USFA, unsaturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; *P < 0.05Lipids in Health and Disease 2005, 4:30 http://www.lipidworld.com/content/4/1/30
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however is that the rigorous nature of the intervention
necessarily minimises the length of the trial. It has been
well demonstrated that favourable alterations in diet can
result in favourable alterations in serum lipids and lipo-
proteins over periods as short as 2–3 weeks [31,32], and
that efficacy of putative lipid lowering dietary therapies
following stabilisation of serum lipid endpoints can be
established within 21 days [31-34]. It was on the basis of
this information that we established the protocol for this
trial and were interested to establish useful short-term
serum lipid markers.
Our current trial showed that even on a diet containing as
much as 15–20 % of energy as SFAs, RBC fatty acid
biomarkers provide a very poor estimate of intake. As per
the trial design, with the exception of the marine oil EPA,
all measured dietary fatty acids altered in response to the
inclusion of the high-SFA and high-USFA dairy lipid into
the diet. The change in RBC profile in response to these
dietary changes was significant in 5 of the 12 measured
fatty acids, palmitic (C16:0), stearic (C18:0), oleic
(C18;1), AA (C20:4) and DHA (C22:6), of which only the
MUFA oleic acid and the LCPUFA DHA were significantly
correlated with diet on the final day of the intervention,
day 21. Despite significant differences in dietary content
of both SFAs C15:0 and C17:0 there was no evidence in
this relative short-term trial that RBC fatty acids can be
used as a reliable biomarker for intake.
In an observational study of 62 older men Smedman and
colleagues [9] have previously shown total C15:0 content
of serum cholesterol esters (CE) and phospholipids to be
a reasonable marker for longterm intake of milk lipids,
estimated using 7 day food records. Wolk and co-workers
[10] also found a significant correlation between CE and
phospholipids C15:0 and habitual diet assessed more rig-
orously by 2 weighed food records and fourteen 24-h diet
recall interviews over a period of 12 months. Alternately,
a group working in Japan presumably on a relatively low-
dairy high-fish consuming population, were unable to
find any relationship between dietary and serum phos-
pholipid SFAs in an observational trial of 87 men [12].
None of these trials addressed the issue of compliance to
changes during intervention protocols. Zock [14] had ear-
lier reported that analysis of a combination of different
intervention trials carried out in their laboratory in the
Netherlands, every 10% of energy fed as a mixture of SFA
lead to an increase in serum CE fatty acid content of 2.2 g/
100 g, and that this was slightly lower for palmitic (1.7 g/
100 g) and myristic (2.1 g/100 g) acid. This compared
badly with changes of 9.3 g/100 g for the n6 PUFA linoleic
acid and 6.5 g/100 g for the MUFA oleic acid. Whilst the
effect of dietary change on RBC fatty acids may be less pro-
nounced than that in plasma, it has been shown to pro-
duce a less variable result [16], which is why it was chosen
for analysis in this validation trial.
Conclusion
In conclusion, we were unable to show a significant corre-
lation between dietary and RBC levels of any saturated
fatty acids in this 3 week, carefully controlled intervention
trial and hence cannot support the use of RBC SFA levels
as a reliable biomarker for intake of dietary SFA [9,10].
Despite a number of potential origins for RBC MUFA in
addition to dietary intake, oleic acid (C18:1) was corre-
lated with diet when there was a high content of USFA. It
was clear that the LCPUFA DHA showed the strongest cor-
relation between diet and RBC levels on all dietary treat-
ments and at all time points, even in this relatively short-
term intervention, confirming it's potential as a reliable
biomarker in trials manipulating marine oils.
Methods
Subjects
Twenty lean male volunteer subjects were recruited into
the study following newspaper advertisements. All sub-
jects were self-motivated to take part in the study, agreed
to maintain the strict regime of dietary control and resi-
dence within the metabolic facility. Subjects were healthy
with no evidence of metabolic or endocrine disorders. All
participants underwent a biochemical screening panel to
ensure good health and completed a brief medical history.
Ethics approval for this study was obtained from the Auck-
land Ethics Committee, Auckland, New Zealand and sub-
jects provided written informed consent.
Protocol
This study was a double-blind, randomised, cross-over
intervention in which a high-saturated fatty acid (high-
SFA, 20 en%) and a high-unsaturated fatty acid (high-
USFA, 24 en%) diet was given to subjects over two periods
of 3 weeks. Subjects were required to be resident at the
University of Auckland Human Nutrition Unit through-
out both dietary intervention periods. All foods and bev-
erages were provided during the interventions and
participants were asked to eat no other foods and to
abstain from drinking alcohol. This ensured that the fatty
acid profile of the diet was controlled and known. The two
intervention periods were 21 days in length and separated
by a minimum washout period of 4 weeks during which
time the volunteers returned home and resumed their
normal diet. Blood samples were routinely collected
throughout the intervention to measure the fatty acid
composition of the erythrocyte membrane. Blood sam-
ples were collected by venipuncture on the morning of
day 1 (pre-intervention baseline), 7, 14 and 21 of each
intervention period following a 12 hour fast. Duplicate
diet portions were prepared throughout the trial and fro-Lipids in Health and Disease 2005, 4:30 http://www.lipidworld.com/content/4/1/30
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zen for later direct measurement of fatty acid composi-
tion.
Dietary intake
Diet was controlled on both intervention arms by provid-
ing participants with all of their dietary requirements. The
intention was to ensure that only trial foods were eaten
and thereby firmly establish the fatty acid profile of the
diet throughout each 3 week period. Participants were
asked to eat all foods provided for them and each diet was
designed on an individual basis to maintain energy bal-
ance through a combination of calculations based on
multiples of predicted basal metabolic rate (BMR), daily
assessment of body weight and discussion of hunger and
satiety levels between participants and the research team.
A 4 day dietary rotation was used during the study such
that every 5th day the entire diet repeated over the 21 days.
Subjects were provided with breakfast, lunch, dinner and
between-meal snacks. Breakfast and dinner were eaten
under supervision at the Nutrition Unit, whilst lunch and
snacks were packed and volunteers were able to take them
to college or their place as work as required. Decaffein-
ated, sugar-free beverages and decaffeinated tea and coffee
were freely available. The 2 diets comprised 40 energy %
(en %) fat, 47 en% CHO and 13 en% protein but differed
considerably in their fatty acid composition (Table 1). The
alteration in fatty acids was made through the inclusion of
a high-SFA or a high-USFA dairy lipid into the diet, details
of which are given in a previous publication [35]. The but-
ter fat provided half of the total fat in the diet (20% of
total energy), scaled to total energy intake and body
weight for each individual. The energy and macronutrient
content of the diet were verified by direct chemical analy-
ses of duplicate diet samples. On 12 occasions during the
intervention a duplicate 4 day diet from a single subject
was collected, homogenised and an aliquot frozen for
later chemical analysis. This enabled the absolute compo-
sition of the diet to be verified.
Blood samples
Venous blood samples were collected into EDTA vacutain-
ers and centrifuged immediately after collection at 3000
rpm for 15 minutes. Supernatant plasma was then
removed. Erythrocytes were washed and transferred into a
-80°C freezer for long-term storage until analysed. The
erythrocyte membrane lipid extraction was based on the
method of Rose and Oklander [36] and used the solid-
phase extraction technique of Kaluzny et al [37]. Frozen,
buffer-washed, packed erythrocytes werethawed at room
temperature and lysed under vortex with purified Milli-Q
water. A chemical preservative of iso-propanol containing
0.005% butylated hydroxytoluene was slowly added to
the cells, under vortex to prevent RBCs caking into a solid
plug, as an anti-oxidant for the PUFAs. Chloroform was
then added with constant vortex mixing and the samples
allowed to stand for 1 hour. The samples were then centri-
fuged at 500 g and the liquid phase containing the eryth-
rocyte membrane lipids removed and evaporated under
an oxygen-free nitrogen stream to concentrate the total
lipid fraction. A three-step solid phase extraction proce-
dure using extract-clean NH2 extraction cartridges (All-
tech, Tennessee, US) on a vacuum manifold was then used
to separate the lipid fractions into neutral lipids, fatty
acids, and phospholipid sub-fractions. The phospholipid
portions were methylated through addition of boron trif-
luoride in methanol (~14% BF3), N2 flushing and heating
to 70°C to form fatty acid methyl esters (FAMEs). Samples
were quantitatively analysed on a gas chromatograph
equipped with an auto injector (Hewlett Packard™ 5890
Series II, Palo Alto, US). Conditions included 0.25 mm
ID, 0.15 µm film thickness J&W DB-225 column; injec-
tion volume 5 µl; injector 240°C; detector 250°C; oven
temperature program 80°C initially ramping to 135°C at
70°C/min after injection and then slowing to 3°C/min.
Blood samples for each individual subject were processed
in parallel to ensure that minor variations in sample han-
dling were minimised.
Statistical analyses
All data was analysed using GraphPad Prism version 4.03
for Windows, (GraphPad Software, San Diego, California,
USA). Paired t-tests were carried out for between-treat-
ment comparison of diet, including energy intake, macro-
nutrient and fatty acid composition, and between-
treatment comparison of erythrocyte fatty acid profile at
day 21. Two-way ANOVA was performed to analyse
change in RBC fatty acid composition over time between
baseline on day 1 and the end of the intervention on day
21 for both dietary treatments. Pearson correlations
between dietary and RBC fatty acids were performed on
day 1, d7, d14 and d21 of the intervention. Statistical sig-
nificance was based on 95% confidence limits (P < 0.05).
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ALA Alpha-linolenic acid
ANOVA Analysis of variance
AA Arachidonic acid
BMI Body mass index
BMR Basal metabolic rate
CE Cholesterol Ester
DHA Docosahexaenoic acid
EDTA Ethylenediaminetetraacetic acidLipids in Health and Disease 2005, 4:30 http://www.lipidworld.com/content/4/1/30
Page 9 of 10
(page number not for citation purposes)
En % Energy %
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